Gene · 5142
PDE4B: phosphodiesterase 4B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PDE4B: phosphodiesterase 4B. Genes, record 5142. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5142
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q07343 | 3',5'-cyclic-AMP phosphodiesterase 4B | 736 | 43 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 57714 | Q07343 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 57715 | Q07343 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 57717 | Q07343 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5945 | Q07343 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5680 | Q07343 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5038 | Q07343 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5680 | Q07343 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5945 | Q07343 | Espacenet |
| JP 2025081323 A | 2025-05-27 | 8 | Q07343 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5038 | Q07343 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs31
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMINOPHYLLINE | CHEMBL1370561 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| AMLEXANOX | CHEMBL1096 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| APREMILAST | CHEMBL514800 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| CILOMILAST | CHEMBL511115 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| CRISABOROLE | CHEMBL484785 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DIFAMILAST | CHEMBL3989968 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DIPYRIDAMOLE | CHEMBL932 | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | ChEMBL |
| DOVRAMILAST | CHEMBL4297460 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DROTAVERINE | CHEMBL551978 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DYPHYLLINE | CHEMBL1752 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 31
See all 31 drugsTrials534
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07566351 | ROFLUMILAST | PHASE2 | ClinicalTrials.gov | |
| NCT07543640 | ROFLUMILAST | PHASE2 | ClinicalTrials.gov | |
| NCT07537751 | CRISABOROLE | ClinicalTrials.gov | ||
| NCT07519174 | CRISABOROLE | ClinicalTrials.gov | ||
| NCT07438509 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07437534 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07398651 | APREMILAST | ClinicalTrials.gov | ||
| NCT07367932 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07366268 | APREMILAST | ClinicalTrials.gov | ||
| NCT07349472 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 534
See all 534 trialsNIH grants1,398
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PDE4B papers | Newest fiscal year |
|---|---|---|---|
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 9 | 2025 |
| R01DA054869 | 7/7 Psychiatric Genomics Consortium: Advancing Discovery and Impact | 6 | 2025 |
| DP1DA054394 | Building Bridges to Allow Cross-species Translational genetics for the Study of Addiction | 5 | 2025 |
| I01BX004820 | Genetic Vulnerability for Sustained Multi-Substance Use in MVP | 5 | 2025 |
| K01AA030083 | Mass Multivariate Derivation and Validation of AUD Biotypes using Developmental Imaging and Genomic Approaches | 5 | 2025 |
| K01DA051759 | Identifying genetic sources of comorbidity between cannabis and schizophrenia using genome-wide and integrative omics data | 5 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 5 | 2025 |
| P50AA012870 | Center for the Translational Neuroscience of Alcoholism | 5 | 2025 |
| ZIAMH002793 | PET Radiopharmaceutical Sciences | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
1 to 10 of 1,398Source NIH's project files
See all 1,398 nih grantsPapers1,785
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis. | Genes Cells | 2026 | 42827411 | PubTator, text mining | PubMed |
| Endoplasmic reticulum stress and maladaptive repair in fibrotic interstitial lung diseases: A human-evidence-based narrative review. | Ther Adv Respir Dis | 2026 | 42813994 | PubTator, text mining | PubMed |
| The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis. | Expert Rev Clin Pharmacol | 2026 | 42768757 | PubTator, text mining | PubMed |
| MiR-23b-3p exerts a protective effect in hypertensive nephropathy by inhibiting fibrosis and inflammation. | Am J Hypertens | 2026 | 42726087 | PubTator, text mining | PubMed |
| Reconfiguring the macrophage-centric intercellular network in pulmonary fibrosis: Emerging perspectives and therapeutic opportunities. | Pharmacol Res | 2026 | 42705427 | PubTator, text mining | PubMed |
| ALDH2 regulates oxaliplatin sensitivity via PDE4B in p53-mutant colorectal cancer. | Int J Med Sci | 2026 | 42694559 | PubTator, text mining | PubMed |
| Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers. | Eur J Drug Metab Pharmacokinet | 2026 | 42563128 | PubTator, text mining | PubMed |
| Elucidating the molecular mechanisms of paeoniflorin intervention in oral lichen planus: a computational biology and bioinformatics-based research strategy. | Front Bioinform | 2026 | 42539528 | PubTator, text mining | PubMed |
| Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis. | J Pharm Technol | 2026 | 42490950 | PubTator, text mining | PubMed |
| Selective phosphodiesterase 4B inhibition in fibrotic lung disease: a scoping review of vascular-immune mechanisms and extrapulmonary implications. | Eur Respir Rev | 2026 | 42486502 | PubTator, text mining | PubMed |
1 to 10 of 1,785
See all 1,785 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5142
GET https://conductscience.org/api/genes/v1/5142/patents?page=2